Eli Lilly to Present New Cardiometabolic Data at EASD 2026
Indianapolis, Indiana, September 15, 2026 Eli Lilly and Company will present new clinical and scientific data for Foundayo (orforglipron),...
EGFR inhibitor
Advertisement
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
BlossomHill Therapeutics Gains FDA Fast Track for BH-30643
San Diego, California, August 18, 2026 BlossomHill Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Verastem Oncology Doses First Patient in TARGET-D 203 Trial
BOSTON, July 28, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 203 Phase...
Syndax Unveils SNDX-4321, Expands Pipeline
NEW YORK, July 14, 2026 Syndax Pharmaceuticals unveiled two new pipeline candidates during its 2026 R&D Event, expanding its...
Advertisements
Dizal Licenses Zegfrovy to AstraZeneca in $1.5B Deal
SHANGHAI, China, July 14, 2026 Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy...
Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
Bayer’s Asundexian Wins FDA Priority Review
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
Advertisement
